4//SEC Filing
Krishnan Suma 4
Accession 0001298711-25-000009
CIK 0001711279other
Filed
Jul 15, 8:00 PM ET
Accepted
Jul 16, 6:42 PM ET
Size
21.2 KB
Accession
0001298711-25-000009
Insider Transaction Report
Form 4
Krishnan Suma
DirectorPresident, R&D10% Owner
Transactions
- Sale
Common Stock
2025-07-15$150.68/sh−2,236$336,929→ 1,441,040 total - Sale
Common Stock
2025-07-15$150.68/sh−2,184$329,089→ 1,510,345 total(indirect: By Spouse) - Sale
Common Stock
2025-07-14$151.00/sh−100$15,100→ 1,443,276 total - Sale
Common Stock
2025-07-16$150.00/sh−1,389$208,350→ 1,508,056 total(indirect: By Spouse) - Sale
Common Stock
2025-07-14$150.29/sh−13,335$2,004,125→ 1,443,376 total - Sale
Common Stock
2025-07-15$151.79/sh−800$121,432→ 1,440,240 total - Sale
Common Stock
2025-07-15$151.79/sh−900$136,611→ 1,509,445 total(indirect: By Spouse) - Sale
Common Stock
2025-07-16$150.00/sh−1,529$229,350→ 1,438,711 total - Sale
Common Stock
2025-07-14$150.30/sh−13,400$2,014,015→ 1,512,529 total(indirect: By Spouse)
Holdings
- 50,000(indirect: By Trust)
Common Stock
- 90,000(indirect: By Trust)
Common Stock
Footnotes (9)
- [F1]The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
- [F2]The transaction was executed in multiple trades ranging from $150.00 to $150.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The transaction was executed in one trade.
- [F4]The transaction was executed in multiple trades ranging from $150.21 to $151.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
- [F6]The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
- [F7]The transaction was executed in multiple trades ranging from $150.00 to $150.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F8]Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.
- [F9]The transaction was executed in multiple trades ranging from $150.21 to $151.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Documents
Issuer
Krystal Biotech, Inc.
CIK 0001711279
Entity typeother
Related Parties
1- filerCIK 0001298711
Filing Metadata
- Form type
- 4
- Filed
- Jul 15, 8:00 PM ET
- Accepted
- Jul 16, 6:42 PM ET
- Size
- 21.2 KB